Current Report Filing (8-k)
November 06 2018 - 4:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
November 6, 2018
IOVANCE BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
|
(State of Incorporation)
|
|
001-36860
|
|
75-3254381
|
Commission File Number
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
999 Skyway Road, Suite 150
|
|
|
San Carlos, California
|
|
94070
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
|
(650) 260-7120
|
(Registrant’s Telephone Number, Including Area Code)
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
|
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company
¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying
with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On November 6, 2018, the Company issued
a press release announcing its financial results for the third quarter ended September 30, 2018 and an update on recent developments.
A copy of that press release is furnished as Exhibit 99.1.
The information furnished under this Item
2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of
the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of such section, nor
shall such information be deemed to be incorporated by reference in any subsequent filing by the Company under the Securities Act
of 1933 or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated in
such filing.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: November 6, 2018
|
IOVANCE BIOTHERAPEUTICS, INC.
|
|
|
|
|
|
By:
/s/ MARIA FARDIS
|
|
Maria Fardis, Chief Executive Officer
|
|
|
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Sep 2023 to Sep 2024